Related references
Note: Only part of the references are listed.Factors Associated with Adherence to Treatment with Isoniazid for the Prevention of Tuberculosis amongst People Living with HIV/AIDS: A Systematic Review of Qualitative Data
Titilola Makanjuola et al.
PLOS ONE (2014)
Estimated Prevalence of Tuberculosis Infection Among a New York City Clinic Population Using Interferon-gamma Release Assays
Natalie L. Stennis et al.
OPEN FORUM INFECTIOUS DISEASES (2014)
Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada
P. W. Colson et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States
D. Shepardson et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia
Mesele Mindachew et al.
BMC PUBLIC HEALTH (2011)
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adherence to treatment of latent tuberculosis infection in a clinical population in New York City
Jiehui Li et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Use of isoniazid for latent tuberculosis infection in a public health clinic
PA LoBue et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Share Paper
